Súhrnná správa o zákazkách s nízkymi hodnotami za obdobie 01-03/2021
Názov zákazky: Obstaranie zariadenia na kvantitatívnu polymerázovú reťazovú reakciu (qPCR) a zariadenia na klasickú polymerázovú reťazovú reakciu (PCR).
Predmet zákazky: Predmetom zákazky je obstaranie zariadenia na kvantitatívnu polymerázovú reťazovú reakciu (qPCR) a zariadenia na klasickú polymerázovú reťazovú reakciu (PCR) pre potreby realizácie projektu s názvom „Vývoj vysoko výkonného, citlivého RT-qPCR testu a rýchleho RTLAMP testu na rozlíšenie SARS-CoV-2 a chrípky“ a číslom projektu „PP-COVID-20-0116“.
Hodnota zákazky: 44 998,00 EUR bez DPH
Identifikácia dodávateľa: Hermes LabSystems, s. r. o., Púchovská 12, 83106 Bratislava
Viac informácií o projekte nájdete na: https://www.multiplexdx.com/post/developing-a-high-throughput-sensitive-rt-qpcr-test-and-rapid-point-of-care-rt-lamp-test-for-the-differentiation-of-sars-cov-2-and-influenza-cov-infect
MultiplexDX is one of the most innovative biotech corporations, created to bring its revolutionary technologies to the market of personalized molecular diagnostics. The company has representation in both U.S. and European markets. The collaborators of MultiplexDX are from the world’s most prestigious scientific organizations including the National Cancer Institute, Rockefeller University, Albert Einstein University, Vanderbilt University, Cornell University, Queens University (Canada), Hebrew University of Jerusalem (Israel), and the Max Delbrück Center for Molecular Medicine (Germany).
MultiplexDX IP-based and innovative platform merges histopathology methods, biomarker quantification, visualization and gene expression with a single-cell resolution by combining MDX proprietary visual and sequencing technologies into one diagnostic test. This cross-validation approach eliminates diagnostic errors and creates 100% precise cancer profiling for each patient which allows clinicians to suggest specific, personalized cancer treatment.
Find out more about MultiplexDX on Corporate website, Facebook, LinkedIn, Twitter
